Rosen Law Firm filed a securities fraud class action against ARS Pharmaceuticals covering purchases between March 9 and June 24, 2026. The lawsuit alleges the company concealed delays in neffy insurance coverage through CVS Caremark. Shares fell 23.9 percent to $8.02 after the company disclosed the coverage delay.
ARS Pharmaceuticals faces a securities fraud class action after SPRY fell 24 percent on delayed neffy coverage.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," Peretz Bronstein, founding partner at Bronstein, Gewirtz & Grossman, said.
The complaint alleges defendants made false statements about the expected timeline for expanded insurance coverage for neffy, the company's epinephrine nasal spray, through CVS Caremark. Company statements expressed confidence that coverage would begin July 1, 2026, in time for the summer and back-to-school allergy seasons. On June 24, ARS said no new commercial formulary additions or coverage decisions had been issued for the July 1 cycle, and CVS Caremark reserved its decision until January 2027. Shares fell $2.52, or 23.9 percent, to close at $8.02 on June 25.
Investors have until October 5, 2026, to request the court appoint them as lead plaintiff. The class action seeks to recover damages for alleged violations of federal securities laws.
Multiple firms have announced similar actions, including Kaplan Fox & Kilsheimer, Pomerantz LLP, and Bronstein, Gewirtz & Grossman. The firms represent investors on a contingency fee basis, with fees paid only if the case succeeds. Kaplan Fox has recovered more than $10 billion for clients since its founding in 1956, while Pomerantz has pursued securities class actions for more than 85 years.
The lawsuit centers on whether ARS and certain officers concealed material adverse facts about the neffy coverage timeline. The company's statements about coverage beginning in time for the summer and back-to-school allergy seasons were allegedly false and misleading, causing shareholders to purchase ARS securities at artificially inflated prices. When the true details entered the market, investors suffered damages.
The October 5 lead plaintiff deadline is the next key date for affected investors. The outcome of the litigation could determine whether shareholders recover losses from the stock's 24 percent decline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation, and investors who do not seek that role can still share in any potential recovery.
This article is for informational purposes only and does not constitute investment advice.
